Helena C. Bartels

Helena C. Bartels

Auto-generated profile, based on publicly available information

Helena C. Bartels

Dept of UCD Obstetrics and Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Holles Street, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Disease Markers
Verified
Journal Article
Open access
PDF file
HBHelena C. Bartels
Helena C. Bartels
JPJames D. Postle
James D. Postle
PDPaul Downey
Paul Downey
DBDonal J Brennan
Donal J Brennan
Background. Placenta accreta spectrum (PAS) is a condition of abnormal placental invasion encompassing placenta accreta, increta, and percreta and is a major cause of severe maternal morbidity and mortality. The diagnosis of a PAS is made on the basis of histopathologic examination and characterised by an absence of decidua and chorionic villi are seen to directly adjacent to myometrial fibres. The underlying molecular biology of PAS is a complex process that requires further research; for ease, we have divided these processes into angiogenesis, proliferation, and inflammation/invasion. A number of diagnostic serum biomarkers have been investigated in PAS, including human chorionic gonadotropin (HCG), pregnancy-associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP). They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive. In summary, there are a limited number of studies that have contributed to our understanding of the molecular biology of PAS, and additional biomarkers are needed to aid diagnosis and disease stratification.

1 June 2020 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
HBHelena C Bartels
Helena C Bartels
JPJames Postle
James Postle
ARAilin C Rogers
Ailin C Rogers
DBDonal Brennan
Donal Brennan
Objective The aim of this systematic review and meta-analysis was to review evidence supporting the use of prophylactic human papillomavirus (HPV) vaccines to influence the risk of recurrence of cervical intraepithelial neoplasia after surgical treatment. Methods A systematic literature search was performed for publications reporting risk of recurrence of cervical intraepithelial neoplasia after surgical treatment in patients receiving HPV vaccination (either in the prophylactic or adjuvant setting). Comprehensive searches of six electronic databases (MEDLINE, Embase, Web of Science, PubMed, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and references of identified studies) from their inceptions were performed (English language only), and hand search reference lists were performed. Two independent reviewers applied inclusion and exclusion criteria to select manuscripts, with differences discussed and agreed by consensus. The literature search was performed using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results A total of 5744 citations were reviewed and five studies comprising 3562 patients were selected for analysis. There were 1453 patients in the vaccinated group and 2109 in the placebo or unvaccinated group. The incidence of histologically confirmed cervical intraepithelial neoplasia 2+ was reduced in the vaccinated compared with the unvaccinated group (OR 0.51, 95% CI 0.35 to 0.74, p=0.0003). The number needed to treat (NNT) to prevent one recurrence was 43. Both pre-treatment vaccination (OR 0.48, 95% CI 0.25 to 0.94, p=0.03, NNT 38) and adjuvant vaccination (OR 0.53, 95% CI 0.34 to 0.81, p=0.004, NNT 40) reduced recurrence rates. Conclusion Prophylactic or adjuvant HPV vaccination reduces the risk of recurrent cervical intraepithelial neoplasia 2+. These data support further investigation of its role as an adjuvant to surgical treatment.

25 March 2021 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
PDF file
HBHelena C. Bartels
Helena C. Bartels
KTKristen Terlizzi
Kristen Terlizzi
NCNaomi Cooney
Naomi Cooney
AKAthina Kranidi
Athina Kranidi
MCMartina Cronin
Martina Cronin
DBDonal J Brennan
Donal J Brennan
Background and Aims: Little is known about the impact of Placenta Accreta Spectrum (PAS) on quality of life (QoL). This study aims to explore QoL and sexual function after a pregnancy complicated by PAS.Methods: Women who experienced a pregnancy complicated by PAS were invited to complete an online survey. Two validated surveys were completed: Short Form 36 (SF‐36) and Female Sexual Function Index (FSFI). The mean scores were calculated and were compared between women by pregnancy outcomes. Continuous variables were presented as mean (standard deviation (SD)) and were compared to assess for significance between groups using independent t‐test and one‐way analysis of variance. Categorical variables were compared using χ2 test.Results: A total of 142 women responded to the survey. For the SF‐36, physical health was significantly higher for women at 24–36 months postpartum compared to those from 0–6 months postpartum for physical functioning (mean difference 21.9 (95% confidence interval (CI) 10.2, 33.5), role limitation due to physical function (mean difference 32.1 (95% CI 9.4, 54.7)) and pain (mean difference 15.5 (95% CI 3.4, 30.9)). For the mental health domains, only vitality improved at 24–36 months compared to the first six months postpartum (mean difference 12.8 (95% CI 0.2, 25.5)). The mean FSFI score was 24.8 (±5.8), lower than the critical score of 26.5 indicating sexual dysfunction, and 56.8% (n = 75), scored less than 26.5.Conclusion: Women after a pregnancy complicated by PAS had high scores on the physical health domains of SF‐36. The mental health scores were lower for all women regardless of time since birth.

24 July 2024 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
HBHelena C. Bartels
Helena C. Bartels
PDPaul Downey
Paul Downey
DBDonal J. Brennan
Donal J. Brennan
Placenta accreta spectrum (PAS) is a relatively new obstetric condition which, until recently, was poorly understood. The true incidence is unknown because of the poor quality and heterogeneous diagnostic criteria. Classification systems have attempted to provide clarity on how to grade and diagnose PAS, but these are no longer reflective of our current understanding of PAS. This is particularly true for placenta percreta, which referred to extrauterine disease, as recent studies have demonstrated that placental villi associated with PAS have minimal potential to invade beyond the uterine serosa. It is accepted that PAS is a direct consequence of previous iatrogenic uterine injury, most commonly a previous cesarean section. Here, we “look back to look forwards”—starting with the primary predisposing factor for PAS, an iatrogenic uterine injury and subsequent wound healing. We then consider the evolution of definitions and diagnostic criteria of PAS from its first description over a century ago to current classifications. Finally, we discuss why modifications to the current classifications are needed to allow accurate diagnosis of this rare but life‐threatening complication, while avoiding overdiagnosis and potential patient harm.

1 November 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
HBHelena C Bartels
Helena C Bartels
KMKaren M Mulligan
Karen M Mulligan
JLJoan G Lalor
Joan G Lalor
MHMary F Higgins
Mary F Higgins
DBDonal J Brennan
Donal J Brennan

28 September 2024 in Translational Research
Verified
Journal Article
Open access
HBHelena C Bartels
Helena C Bartels
SHSodiq Hameed
Sodiq Hameed
CYConstance Young
Constance Young
MNMyriam Nabhan
Myriam Nabhan
PDPaul Downey
Paul Downey
DBDonal J Brennan
Donal J Brennan
In severe Placenta Accreta Spectrum (PAS), trophoblasts gain deep access in the myometrium (placenta increta). This study investigated alterations at the fetal-maternal interface in PAS cases using a systems biology approach consisting of immunohistochemistry, spatial transcriptomics and proteomics. We identified spatial variation in the distribution of CD4+, CD3+ and CD8+ T-cells at the maternal-interface in placenta increta cases. Spatial transcriptomics identified transcription factors involved in promotion of trophoblast invasion such as AP-1 subunits ATF-3 and JUN, and NFKB were upregulated in regions with deep myometrial invasion. Pathway analysis of differentially expressed genes demonstrated that degradation of extracellular matrix (ECM) and class 1 MHC protein were increased in increta regions, suggesting local tissue injury and immune suppression. Spatial proteomics demonstrated that increta regions were characterised by excessive trophoblastic proliferation in an immunosuppressive environment. Expression of inhibitors of apoptosis such as BCL-2 and fibronectin were increased, while CTLA-4 was decreased and increased expression of PD-L1, PD-L2 and CD14 macrophages. Additionally, CD44, which is a ligand of fibronectin that promotes trophoblast invasion and cell adhesion was also increased in increta regions. We subsequently examined ligand receptor interactions enriched in increta regions, with interactions with ITGβ1, including with fibronectin and ADAMS, emerging as central in increta. These ITGβ1 ligand interactions are involved in activation of epithelial-mesenchymal transition and remodelling of ECM suggesting a more invasive trophoblast phenotype. In PAS, we suggest this is driven by fibronectin via AP-1 signalling, likely as a secondary response to myometrial scarring.